• news.cision.com/
  • IRRAS/
  • Presentation of Largest Dataset to Date Documenting Use of IRRAflow System Confirms Improved Outcomes Compared to Traditional Drainage Solutions

Presentation of Largest Dataset to Date Documenting Use of IRRAflow System Confirms Improved Outcomes Compared to Traditional Drainage Solutions

Report this content
  • Surgeons from West Virginia University Hospital presented data from the hospital’s treatment of its first 45 patients using the IRRAflow system across multiple intracranial disease states.
  • The presented data demonstrated that the use of IRRAflow resulted in a 0% catheter occlusion rate, a decreased percentage of observed vasospasm, and a reduced need for shunt placement after treatment when compared to historic published rates.

Stockholm, February 10, 2022 – IRRAS, a commercial-stage medical technology company with a comprehensive portfolio of innovative products for neurocritical care, today announced the presentation of the largest dataset to date to document clinical outcomes using its IRRAflow system.  The neurosurgery team from the Rockefeller Neuroscience Institute at West Virginia University and WVU Medicine Ruby Memorial Hospital (WVUH), led by Dr. Nicholas Brandmeir, tracked the outcomes from the first 45 patients that they treated with IRRAflow across a variety of intracranial pathologies, and their positive initial results were presented by Dr. Babar Khan at the Neurosurgical Society of the Virginias annual meeting in White Sulphur Springs, West Virginia, on January 27, 2022. 

The presented data confirmed the effectiveness of the IRRAflow system’s automated irrigation by showing a 0% occlusion rate during the entire course of treatment.  Traditional passive drainage solutions, on the other hand, have catheter occlusion rates up to 47% documented in clinical literature.  Additionally, IRRAflow’s mechanism of action was also shown to more effectively remove collected blood after intracranial bleeding.  Average treatment time with IRRAflow was 6.8 days, and only 13% of patients required the placement of a shunt after IRRAflow treatment.  This percentage of shunt dependence with IRRAflow compares favorably to data from the CLEAR-III where 18% of patients required shunt placement after treatment with a passive ventricular drain. 

The WVUH data also highlighted a reduction of vasospasm observed after ruptured cerebral aneurysms compared to higher historic published rates.  After intracranial bleeding occurs, the collected blood induces an inflammatory response, which can cause the vessels in the brain to spasm or narrow, limiting blood flow, and putting the patient at risk for a secondary stroke. IRRAflow’s more efficient removal of collected blood resulted in decreased observation of this deadly vasospasm phenomenon.

These positive outcomes that highlight the IRRAflow system’s effectiveness were collected across a wide range of intracranial pathologies, including intraventricular hemorrhage (IVH), ventriculitis, subarachnoid hemorrhage, and subdural hematomas. This data set also serves to further expand the available clinical evidence to document IRRAflow’s ability to safely perform targeted drug delivery with positive results.  The WVUH team has delivered medication with IRRAflow to treat 24.4% of their patients to date.

“This data presented by the surgeons from the Rockefeller Neuroscience Institute at West Virginia University further confirms the positive impact that our IRRAflow system is having on a growing number of patients around the world,’ said Will Martin, President and Chief Executive Officer of IRRAS. “Our key corporate objective in 2022 is to document the superiority of our products with robust clinical data, and this early data shows that the use of IRRAflow can result in better patient outcomes, decreased length of hospitalization, and reduced overall cost of care.”

The presentation can be viewed at the following link:



IRRAS is a global medical care company focused on delivering innovative medical solutions to improve the lives of critically ill patients. IRRAS designs, develops, and commercializes neurocritical care products that transform patient outcomes and decrease the overall cost of care by addressing complications associated with current treatment methodologies. IRRAS markets and sells its comprehensive, innovative IRRAflow and Hummingbird ICP Monitoring product lines to hospitals worldwide through its direct sales organization in the United States and select European countries as well as an international network of distribution partners.

IRRAS maintains its headquarters in Stockholm, Sweden, with corporate offices in Munich, Germany, and San Diego, California, USA. For more information, please visit www.irras.com.

IRRAS is listed on Nasdaq Stockholm (ticker: IRRAS).

For more information, please contact:

Sten Gustafsson
Director, Investor Relations
+46 102 11 5172

The information was released for public disclosure, through the agency of the contact person above, on February 10, 2022, at 8:30 (CET).